Core Viewpoint - The acquisition plan of Chengdu Xian Dao Pharmaceutical Development Co., Ltd. for 65% equity of Nanjing Haina Pharmaceutical Technology Co., Ltd. has been terminated due to disagreements on key terms such as transaction structure, price, and performance commitments [1][2][6]. Group 1: Acquisition Details - Chengdu Xian Dao signed a letter of intent to acquire 65% of Haina Pharmaceutical on March 31, 2025, which initially led to a positive market reaction with an 8.65% stock price increase [4]. - The acquisition was seen as a strategic move for Chengdu Xian Dao to transition from a DEL technology provider to a comprehensive CRDMO platform, potentially competing with major players like WuXi AppTec [6][7]. Group 2: Financial Performance - Haina Pharmaceutical reported a revenue of 271 million yuan and a net profit of 68.01 million yuan in 2022, with a net profit of 73.18 million yuan achieved in the first half of 2023 [5]. Group 3: Market Reaction - Following the announcement of the termination, Chengdu Xian Dao's stock price experienced volatility, opening at 15.70 yuan, dropping to a low of 14.96 yuan, and closing at 16.08 yuan, reflecting a decline of 0.99% [3]. Group 4: Future Outlook - Despite the termination of the acquisition, both companies expressed mutual recognition and indicated the possibility of exploring future business collaboration opportunities [7].